WPD Pharmaceuticals Company
WPD on April 9 said independent research on WP1122 found 2-DG to reduce replication of SARS-CoV-2 by 100% in in vitro testing. WPD and CNS intend to move into clinical trials of WP1122 and other preclinical drugs on SARS-CoV-2 and other viruses. WPD has licensed a portfolio of drug candidates from Moleculin Biotech.
Technology:
COVID
Industry:
Treatments
Headquarters:
Canada
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership